ACSL3 Promotes Intratumoral Steroidogenesis in Prostate Cancer Cells

Overview

Journal Cancer Sci

Specialty Oncology

Date 2017 Aug 4

PMID 28771887

Citations 35

Authors

Toshiro Migita

Ken-Ichi Takayama

Tomohiko Urano

Daisuke Obinata

Kazutaka Ikeda

Tomoyoshi Soga

Satoru Takahashi

Satoshi Inoue

Affiliations

Soon will be listed here.

Abstract

Long-chain acyl-coenzyme A (CoA) synthetase 3 (ACSL3) is an androgen-responsive gene involved in the generation of fatty acyl-CoA esters. ACSL3 is expressed in both androgen-sensitive and castration-resistant prostate cancer (CRPC). However, its role in prostate cancer remains elusive. We overexpressed ACSL3 in androgen-dependent LNCaP cells and examined the downstream effectors of ACSL3. Furthermore, we examined the role of ACSL3 in the androgen metabolism of prostate cancer. ACSL3 overexpression led to upregulation of several genes such as aldo-keto reductase 1C3 (AKR1C3) involved in steroidogenesis, which utilizes adrenal androgen dehydroepiandrosterone sulfate (DHEAS) as substrate, and downregulated androgen-inactivating enzyme UDP-glucuronosyltransferase 2 (UGT2B). Exposure to DHEAS significantly increased testosterone levels and cell proliferative response in ACSL3-overexpressing cells when compared to that in control cells. A public database showed that ACSL3 level was higher in CRPC than in hormone-sensitive prostate cancer. CRPC cells showed an increased expression of ACSL3 and an expression pattern of AKR1C3 and UGT2B similar to ACSL3-overexpressing cells. DHEAS stimulation significantly promoted the proliferation of CRPC cells when compared to that of LNCaP cells. These findings suggest that ACSL3 contributes to the growth of CRPC through intratumoral steroidogenesis (i.e. promoting androgen synthesis from DHEAS and preventing the catabolism of active androgens).

Citing Articles

Crosstalk between gut microbiotas and fatty acid metabolism in colorectal cancer.

Zhang H, Tian Y, Xu C, Chen M, Xiang Z, Gu L Cell Death Discov. 2025; 11(1):78.

PMID: 40011436 PMC: 11865559. DOI: 10.1038/s41420-025-02364-5.

Bioinformatics insights into ACSL1 and ACSL5: prognostic and immune roles in low-grade glioma.

Zhang C, Lv Z, Liang H, Hu F, Bi H BMC Cancer. 2025; 25(1):226.

PMID: 39924494 PMC: 11809057. DOI: 10.1186/s12885-025-13651-w.

Dysregulation of genes involved in the long-chain fatty acid transport in pancreatic ductal adenocarcinoma.

Poenaru R, Milanesi E, Niculae A, Dobre A, Vladut C, Ciocirlan M World J Gastrointest Oncol. 2025; 17(1):98409.

PMID: 39817147 PMC: 11664611. DOI: 10.4251/wjgo.v17.i1.98409.

The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors.

Liaghat M, Ferdousmakan S, Mortazavi S, Yahyazadeh S, Irani A, Banihashemi S Cell Commun Signal. 2024; 22(1):575.

PMID: 39623377 PMC: 11610171. DOI: 10.1186/s12964-024-01957-4.

Anillin actin-binding protein expression correlates with poor prognosis for prostate cancer patients.

Yamamoto S, Obinata D, Takayama K, Funakoshi D, Fujiwara K, Hara M Asian J Urol. 2024; 11(4):569-574.

PMID: 39533998 PMC: 11551517. DOI: 10.1016/j.ajur.2023.07.002.

References

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. PMC: 2726827. DOI: 10.1016/j.cell.2009.04.056. View

Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M . ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 2008; 68(20):8547-54. DOI: 10.1158/0008-5472.CAN-08-1235. View

Migita T, Takayama K, Urano T, Obinata D, Ikeda K, Soga T . ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells. Cancer Sci. 2017; 108(10):2011-2021. PMC: 5623750. DOI: 10.1111/cas.13339. View

Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A . Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact. Am J Pathol. 2013; 182(5):1800-10. DOI: 10.1016/j.ajpath.2013.01.048. View

Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W . Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 2007; 67(11):5117-25. DOI: 10.1158/0008-5472.CAN-06-4040. View

Cai C, Balk S . Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011; 18(5):R175-82. PMC: 3815562. DOI: 10.1530/ERC-10-0339. View

Mostaghel E, Marck B, Plymate S, Vessella R, Balk S, Matsumoto A . Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011; 17(18):5913-25. PMC: 3184252. DOI: 10.1158/1078-0432.CCR-11-0728. View

Knudsen K, Penning T . Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010; 21(5):315-24. PMC: 2862880. DOI: 10.1016/j.tem.2010.01.002. View

Bao B, Chuang B, Wang Q, Sartor O, Balk S, Brown M . Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate. 2008; 68(8):839-48. PMC: 2703184. DOI: 10.1002/pros.20749. View

10.

Takayama K, Misawa A, Suzuki T, Takagi K, Hayashizaki Y, Fujimura T . TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun. 2015; 6:8219. DOI: 10.1038/ncomms9219. View

11.

Hofland J, van Weerden W, Dits N, Steenbergen J, van Leenders G, Jenster G . Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010; 70(3):1256-64. DOI: 10.1158/0008-5472.CAN-09-2092. View

12.

Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T . SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011; 29(18):2565-73. PMC: 3138634. DOI: 10.1200/JCO.2010.31.2405. View

13.

Swinnen J, Heemers H, Van de Sande T, De Schrijver E, Brusselmans K, Heyns W . Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol. 2005; 92(4):273-9. DOI: 10.1016/j.jsbmb.2004.10.013. View

14.

Barfeld S, Itkonen H, Urbanucci A, Mills I . Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocr Relat Cancer. 2014; 21(4):T57-66. DOI: 10.1530/ERC-13-0515. View

15.

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

16.

Tomlins S, Mehra R, Rhodes D, Cao X, Wang L, Dhanasekaran S . Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2006; 39(1):41-51. DOI: 10.1038/ng1935. View

17.

Miyamoto D, Sequist L, Lee R . Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol. 2014; 11(7):401-12. DOI: 10.1038/nrclinonc.2014.82. View

18.

Csala M, Banhegyi G, Kardon T, Fulceri R, Gamberucci A, Giunti R . Inhibition of glucuronidation by an acyl-CoA-mediated indirect mechanism. Biochem Pharmacol. 1996; 52(7):1127-31. DOI: 10.1016/0006-2952(96)00423-6. View

19.

Bolotin E, Liao H, Ta T, Yang C, Hwang-Verslues W, Evans J . Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target genes using protein binding microarrays. Hepatology. 2010; 51(2):642-53. PMC: 3581146. DOI: 10.1002/hep.23357. View

20.

Chang K, Li R, Papari-Zareei M, Watumull L, Zhao Y, Auchus R . Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2011; 108(33):13728-33. PMC: 3158152. DOI: 10.1073/pnas.1107898108. View